failed

ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…

3 days ago

BYD improves Assisted Driving system in response to Euro NCAPs ATTO 3 grading

LEUVEN, BELGIUM – BYD has responded to the ’Not Recommended’ grading which Euro NCAP gave to the ATTO 3’s Assisted…

3 months ago